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Posttransplant anemia is a common problem that may hinder
patients’ quality of life. It occurs in 12 to 76% of patients, and
is most common in the immediate posttransplant period. A
variety of factors have been identified that increase the risk
of posttransplant anemia, of which the level of renal function
is most important. Sirolimus, a mammalian target of
rapamycin inhibitor, has been implicated as playing a special
role in posttransplant anemia. This review considers anemia
associated with sirolimus, including its presentation,
mechanisms, and management.
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POSTTRANSPLANT ANEMIA: PREVALENCE AND RISK
FACTORS
The prevalence of posttransplant anemia (PTA) depends
greatly on the definition of anemia, with various studies
using different hemoglobin (Hb) threshold levels. On
account of this, the reported prevalence of PTA varies greatly,
from 12 to 94% depending on the time posttransplant
(PT).1–5 Mix et al.,3 in a retrospective study of 240 kidney
transplant recipients, defined anemia as hematocrit levels
o36%. The prevalence of PTA was 76% at the time of
transplant, 21% at 1 year PT, and 36% at 4 years PT. This
pattern of anemia with the highest frequency early PT has
been a consistent finding in the literature.
PTA’s most important risk factor seems to be kidney
allograft function level.2–4,6,7 For example, in a retrospective
study of 459 patients in Ottawa, Canada, Karthikeyan et al.7
found that PTA prevalence increased throughout chronic
kidney disease (CKD) stages: 0, 3, 7, 27, and 33% of kidney
transplant recipients were anemic in stages 1, 2, 3, 4, and 5,
respectively (Figure 1).
Drugs such as immunosuppressants, angiotensin-receptor
blockers, angiotensin-converting enzyme inhibitors, and
antimicrobials have also been associated with PTA.2,4,6,8,9
Regardless of type, maintenance immunosuppressive drugs
may have inhibitory effects on erythropoiesis and result in
PTA.1,2,4,6,8,9 In addition, calcineurin inhibitors (CNIs), that
is, cyclosporin A (CsA) and tacrolimus, and to a lesser extent
mammalian target of rapamycin (mTOR) inhibitors, includ-
ing sirolimus (SRL), are associated with thrombotic micro-
angiopathy.10,11
Finally, age, female gender, iron status, malignancies,
inflammation, and viral infections are other potential risk
factors involved in PTA pathogenesis.2,4,12–15 When these
widely varied pathogenic factors are considered, it is clear
that PTA is often a multifactorial process.16
ASSOCIATION OF ANEMIA WITH OUTCOMES IN CKD AND THE
POTENTIAL APPLICABILITY TO TRANSPLANT PATIENTS
There is a paucity of data relating the relationship of anemia
to outcomes in transplant recipients. The data that exist are
conflicting. Some studies have suggested a strong association
between anemia and worsened mortality and cardiovascular
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complications.17–20 Molnar et al.19 found that anemia
predicted both graft failure and mortality, independent of
covariates. In contrast, the relationship between anemia and
adverse outcomes has not been supported by other
analyses.21–23 Owing to these conflicting results, it would
seem reasonable to briefly evaluate the experience in
nondialysis CKD patients.
There is strong evidence from observational studies that
anemia is associated with worse survival and cardiovascular
outcomes in CKD patients.24–28 Several observational studies
also showed a relationship between anemia and left
ventricular hypertrophy.29 However, the association between
anemia and worse outcomes has not generally been borne out
by randomized studies of complete anemia correction
(comparisons of lower and near-normal Hb targets) using
erythropoiesis-stimulating agents. Smaller studies have sug-
gested the absence of any improvement in outcomes with
complete anemia correction, whereas larger studies have
suggested increased risk. In two recent trials in nondialysis
CKD patients, treatment to higher Hb targets resulted in a
trend of increased risk for death and cardiovascular
events.30,31 The most important positive outcome of treat-
ment studies in nontransplant CKD patients has been an
improvement in patients’ quality of life. Study results have
been inconsistent, but with a general trend toward mean-
ingful improvement.
ANEMIA WITH SIROLIMUS
Before considering the management of PTA, SRL will be
discussed because of recent interest in this agent’s role as a
cause of PTA. SRL has been used in the treatment of renal
transplant recipients in a wide variety of maintenance
immunosuppressive regimens. The multiplicity of uses
complicates the assessment of the independent role SRL
may have in the development of PTA. However, there is
ample circumstantial evidence indicating that SRL is a
contributing factor to PTA in certain settings (Table 1).
In addition, anemia has been seen with the related drug
everolimus.39
Initial phase 1 and 2 dose escalation studies found a slower
recovery of Hb postoperatively in SRL/CsA/prednisone-
treated renal allograft recipients compared with CsA/
prednisone-treated historical controls.32 This seemed to be
SRL dose/trough concentration related. Groth et al.33 noted a
37% incidence of anemia early PT in SRL-treated patients
versus 24% in a CsA-treated group. Gonwa et al.40 found a
similar incidence of anemia (33–34%) comparing SRL/CsA/
corticosteroid maintenance with SRL/CsA/corticosteroids
with subsequent CsA elimination. Kreis et al.34 observed a
43% incidence of anemia with SRL compared with 32% in
the CsA arm in studies in which both treatment arms
received either azathioprine or mycophenolate mofetil
(MMF), perhaps accounting for the overall higher rate of
anemia. By week 24, however, mean Hb values were equal.
A dose relationship between SRL and anemia incidence
was documented in phase 3 trials comparing SRL 2mg/day
with SRL 5mg/day administered along with CsA and
corticosteroids (24 versus 35%, respectively).34 However, in
the control arm, treated with azathioprine, 25% of patients
experienced anemia, no different than the low-dose SRL arm.
A second phase 3 trial comparing SRL/CsA/corticosteroids
with placebo/CsA/corticosteroids found similar results: over-
all, 36% incidence of anemia (SRL 2mg/day) versus 56%
(SRL 5mg/day) versus 16% (placebo).35 Allograft function
was noted to be inferior in the 5-mg/day SRL arm.
In a study comparing SRL/MMF/prednisone with tacro-
limus/MMF/prednisone, mean Hb was again significantly
lower in SRL-treated patients at 1 month, but equivalent at 1
year.36 In contrast, Flechner et al.38 found no difference in
mean Hb at any time PT in CsA/MMF/prednisone- versus
SRL/MMF/prednisone-treated patients, although there was a
trend toward a lower Hb in the latter population. Of note,
allograft function was significantly better in patients receiving
SRL. Friend et al.41 found that long-term use of SRL/
prednisone resulted in a lower prevalence of anemia
compared with SRL/CsA/prednisone, despite higher SRL
concentrations. Again, renal function was significantly better
in the arm not receiving CsA, complicating the interpretation
of these observations.
Augustine et al.8 compared SRL/CNI/corticosteroids with
MMF/CNI/corticosteroids in kidney and kidney–pancreas
recipients. They found a higher prevalence of anemia in the
SRL versus MMF group at 6 months (57 versus 41%,
respectively) and 12 months (57 versus 31%, respectively).
A multivariate analysis that adjusted for potential confoun-
ders identified SRL treatment as an independent risk factor
for anemia. Another study of PTA, despite involving only a
small number of SRL-treated patients, also identified SRL as
an independent risk factor for anemia.37,42
In contrast, Kim et al.37 found essentially no difference in
mean Hb at any time PT between SRL/MMF/prednisone and
CsA/MMF/prednisone. There was a trend toward lower Hb
in the SRL arm at day 61, which reached significance at
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Figure 1 |Prevalence of posttransplant anemia according to
stage of kidney function. CKD, chronic kidney disease;
Hb, hemoglobin. Adapted from Karthikeyan et al.7
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day 91. Hb levels, however, were equivalent in the two arms
by day 183. The two treatment groups had equivalent mean
serum creatinine levels.
Thus, even in the face of multiple confounding and poorly
controlled variables, most of the large initial studies of SRL
use in renal transplant recipients have identified SRL as a
possible cause of PTA, particularly in the period immediately
PT. This effect seems to be dose related, but transient, as Hb
values rise and become equivalent to those in non-SRL-
treated patients by 6 months.
Conversion studies offer the opportunity to observe the
impact of introducing SRL to previously stable patients, and
thereby have the potential to clarify SRL’s independent role in
PTA. Multiple studies have shown that conversion from CNI
to SRL in long-term allograft recipients results in a significant
decline in Hb, suggesting but not proving a direct causative
role. Thaunat et al.43 retrospectively examined the change in
Hb in 46 patients switched from CNI-based immunosup-
pression to SRL-based immunosuppression for chronic
allograft nephropathy/chronic CNI nephrotoxicity at a mean
of 55 months PT. Hb decreased in 86.9% of patients, with a
mean decrease of 2.5 g per 100ml. Nadir Hb levels were
reached afterE3 months. In a subset of patients, the anemia
improved after discontinuation of SRL, providing strong
evidence implicating the conversion to SRL as the cause.
Similar results were obtained by Maiorano et al.44 and
Diekmann et al.45 Compared with maintaining patients on
reduced CsA doses, conversion to SRL resulted in a
significant fall in mean Hb level. The CONVERT trial found
that anemia was reported in 37.4% of patients converted to
SRL versus 18.7% of patients continued on CNI.46 Conver-
sion in lung transplant recipients with obliterative bronch-
iolitis/bronchiolitis obliterans syndrome from azathioprine
or MMF to SRL in combination with CNI and steroids also
resulted in a high incidence of anemia.47
Conclusions on SRL and PTA
Taken together, these data strongly suggest that SRL may be a
contributing factor to PTA. It is impossible, however, to
dissect with any certainty its independent causative role from
the combined effects of SRL administered along with other
immunosuppressants.
MECHANISMS OF SRL-MEDIATED ANEMIA: MICROCYTOSIS
Multiple investigators have noted that red blood cell (RBC)
morphology in SRL-treated patients is characterized by a
decrease in mean corpuscular volume (MCV) –microcytosis.
Kim et al.37 noted a decline in MCV from 91.7 fl at baseline
to 78.5 fl by 6 months in de novo renal transplant recipients
treated with SRL/MMF/prednisone, but without anemia. In
contrast, MCV was unchanged in control patients treated
with CsA/MMF/prednisone. A significant difference in MCV
between the two treatment groups was developed 1 month
PT. The CONVERT trial also documented a fall in MCV
from 90 fl to 82 fl over weeks 2–24 after conversion to SRL.46
Of interest, microcytosis may be progressive, whereas anemia
tends to stabilize. The reasons for this discrepancy are
unclear.
Thaunat et al.43 and Cahill et al.47 observed that anemia
developed in patients converted to SRL from CNI, and it was
Table 1 | Anemia and sirolimus use in maintenance-dosing studies
Authors Study design/compared treatments Summary of findings
Studies finding increased
anemia with SRL use
Kahan et al.32 SRL/CsA/prednisone-treated new renal
allograft recipients
Slower recovery of hemoglobin
postoperatively in SRL-treated patients
CsA/prednisone-treated historical controls
Groth et al.33 SRL early posttransplant 37% incidence of anemia early
posttransplant
CsA treatment early posttransplant 24% incidence of anemia early
posttransplant
Kreis et al.34 SRL-based treatment 43% incidence of anemia
CsA-based treatment 29% incidence of anemia
MacDonald et al.35 SRL/CsA/corticosteroids 16% incidence of anemia (SRL 2mg/day)
versus 27% (SRL 5mg/day)
Placebo/CsA/corticosteroids 13% incidence of anemia
Larson et al.36 SRL/MMF/prednisone Mean hemoglobin was significantly lower
in SRL-treated patients at 1 month, but
equivalent at 1 year
TAC/MMF/prednisone
Augustine et al.8 SRL/CNI/corticosteroids Higher prevalence of anemia with SRL
groups at both 6 and 12 months
MMF/CNI/corticosteroids
Studies not finding
increased anemia with
SRL use
Kim et al.37 SRL/MMF/prednisone No difference in mean hemoglobin at any
time
CsA/MMF/prednisone
Flechner et al.38 CsA/MMF/prednisone No significant difference in mean
hemoglobin
SRL/MMF/prednisone
CNI, calcineurin inhibitor; CsA, cyclosporin A; MMF, mycophenolate mofetil; SRL, sirolimus; TAC, tacrolimus.
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characterized by microcytosis. They also noted low serum
iron levels with normal serum ferritin concentration. This
was interpreted as representing anemia of chronic inflam-
matory disease. Additional support for this concept came
from the elevation in serum levels of inflammatory cytokines.
Maiorano et al.,44 on the other hand, suggested that the
role of SRL in the development of anemia was not due to an
inflammatory state, but rather a direct effect on iron
homeostasis. They found a considerable reduction in MCV,
with a low serum iron level and unchanged serum ferritin
level after switching to SRL from CNI. Hepcidin (a protein
that redirects iron homeostasis in the presence of inflamma-
tion) concentrations tended to be lower in SRL-treated
patients, suggesting that there was no major inflammatory
state.
OTHER MECHANISMS OF SRL-MEDIATED MICROCYTOSIS
The TOR is a highly conserved protein kinase that regulates
cell growth and cell cycle progression. Through coordination
of growth and proliferation, TOR regulates the size of cells,
organs, and organisms. mTOR is best known to regulate
protein translation through the ribosomal protein S6 kinases
and the eukaryotic translation initiation factor 4E-binding
proteins.48
There is crosstalk between TOR and the phosphoinositol-
3-kinase. The TOR and phosphoinositol-3-kinase interac-
tions are important for erythroid progenitor differentiation49
and erythropoietin receptor-mediated proliferation of ery-
throid precursors.50
Inhibition of mTOR by SRL results in diminution of
proliferation of erythroid cell lines in vitro.51 Treatment of
normal human erythroid precursor cells with SRL (at very
high concentrations) also results in rapid differentiation and
fetal Hb production but without inhibition of cell growth
and proliferation.52 There are no reports of whether increased
fetal Hb expression is part of the clinical phenotype of SRL-
associated anemia.
On the basis of the above mechanisms, clinical use of SRL
may result in early differentiation of erythroid precursors and
diminished globin synthesis, contributing to microcytic
anemia. Iron deficiency is common in the renal transplant
population, and can also cause microcytic anemia. It has
been proposed that SRL may somehow induce iron deficiency
through impaired intestinal iron absorption, although there
is insufficient evidence to confirm this hypothesis.44 No
groups have reported on bone marrow iron stores in severely
anemic SRL-treated patients or whether iron administration
is beneficial in such patients.
PTA CLINICAL MANAGEMENT
Helpful guidance for the management of anemia in
kidney disease comes from the National Kidney Foundation
(NKF) Kidney Disease Outcomes Quality Initiative’s
(KDOQI) anemia treatment guidelines. These guidelines
were last updated in May 2006.53 A further update with
specific emphasis on target Hb was published in 2007.54 The
guidelines include a section on anemia in transplant patients,
but there are no guideline statements that specifically address
evaluation or management of PTA. It is not clear to what
extent the general CKD treatment recommendations can be
extrapolated to the management of PTA.
The algorithm in Figure 2 summarizes the authors’
recommendations on diagnostic and therapeutic approaches
to anemia in the PT patient. On account of the high
prevalence of PTA, it is recommended that PT patients be
screened for anemia more often than the once per year
recommended by the NKF KDOQI guidelines for patients
with CKD in general.53 Depending on the frequency of blood
testing for other indications, level of renal function, intensity
of immunosuppression, and presence of comorbid disease, it
is recommended that PT patients have Hb measurement
every 1–3 months. If anemia is detected, evaluation for the
cause of the anemia should be initiated.
As iron deficiency is common in PT patients,55 it is
important that those with anemia be tested for iron
deficiency. The NKF KDOQI anemia guidelines recommend
serum ferritin o100 ng/ml and transferrin saturationo20%
or reticulocyte Hb content o29 pg/cell to diagnose iron
deficiency in nonhemodialysis patients with CKD.53 Oral
iron supplements may be sufficient to correct iron deficiency
in PT patients, and should be given at a dosage that provides
at least 200mg of elemental iron daily. If a trial of oral iron is
ineffective or the magnitude of iron deficiency is profound,
intravenous iron supplementation should be considered.
A thorough history and physical examination are essential
in the evaluation of the anemic PT patient. All anemic PT
patients should have stool tested for occult blood, followed
by upper and/or lower endoscopy if positive. Routine
screening tests for malignancy in the PT patient should be
current, including colonoscopy and mammography and
pelvic exam with Pap smear in women.
As per the NKF KDOQI anemia guidelines for patients
with CKD, the anemia evaluation should also include red cell
indices, a reticulocyte count, and vitamin B12 and folate
levels.53 The reticulocyte count can be helpful in distinguish-
ing anemia that results from underproduction of RBCs from
anemia caused by RBC loss or destruction. The rare
hemolytic-uremic syndrome associated with CsA therapy
leads to intravascular RBC destruction. The presence of
fragmented RBCs on peripheral blood smear supports this
diagnosis.
If there is no evidence of an infectious, inflammatory, or
malignant process and the patient is not nutritionally
deficient, then it is likely the anemia exists because of renal
insufficiency and/or the effects of immunosuppressive or
other medications. Consideration should be given to
discontinuing medications that are not essential but have
been associated with PTA. Of the immunosuppressive agents,
MMF and SRL have been associated with the greatest
prevalence of anemia.15,56,57 Both MMF and SRL suppress
RBC production in a dose-related manner;15 therefore, the
level of these drugs should be measured and dosages adjusted
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accordingly, but only after careful clinical consideration of
their roles in the antirejection regimen. In cases of severe
anemia for which no etiology other than the immunosup-
pressive therapy can be found, consideration may be given to
changing the immunosuppressive regimen.
Often, PTA will arise because of CKD and erythropoietin
deficiency.15,55 After all other etiologies of anemia have been
excluded, the diagnosis of erythropoietin deficiency may be
assumed. The NKF KDOQI anemia guidelines do not
recommend obtaining an erythropoietin level because it is
expensive and usually not helpful. At this point, considera-
tion should be given to initiating erythropoiesis-stimulating
agent therapy if Hb is o10–11 g per 100ml.
CONCLUSIONS
PTA is a common problem that may result in fatigue and
diminished quality of life. The etiology may often be
multifactorial, with the level of renal function the most
important determining factor. Antirejection medications may
contribute to PTA through a variety of mechanisms. SRL
seems to increase PTA risk, with anemia and microcytosis
occurring more frequently in SRL-treated kidney transplant
recipients. The diagnostic approach to PTA is similar to the
general evaluation of anemia in other patient groups. In
many cases, a clear cause will not be determined and a
presumptive diagnosis of relative erythropoietin deficiency
will result. Treatment with erythropoiesis-stimulating agents
can reduce the need for blood transfusion and improve
patients’ quality of life.
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